Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial

DOI Web Site Web Site 被引用文献1件

収録刊行物

The Lancet Rheumatology

The Lancet Rheumatology 5 (8), e442-e450, 2023-08

Elsevier BV

被引用文献 (1)*注記

もっと見る

詳細情報詳細情報について

CRID

1360862408323697920
DOI

10.1016/s2665-9913(23)00157-1
ISSN

26659913
Web Site

https://api.elsevier.com/content/article/PII:S2665991323001571?httpAccept=text/xml

https://api.elsevier.com/content/article/PII:S2665991323001571?httpAccept=text/plain
データソース種別
- Crossref

書き出し

問題の指摘

ページトップへ